148 related articles for article (PubMed ID: 37186414)
1. Hyperhaemolysis caused by anti-HI antibodies in a patient with myelodysplastic syndrome following a first ever red cell transfusion.
Hinton R; Haji R; Kaczmarski R; Layton M; Danga A
Transfus Med; 2023 Aug; 33(4):349-351. PubMed ID: 37186414
[TBL] [Abstract][Full Text] [Related]
2. Post-transfusion hyperhaemolysis in a patient with sickle cell disease: use of steroids and intravenous immunoglobulin to prevent further red cell destruction.
Cullis JO; Win N; Dudley JM; Kaye T
Vox Sang; 1995; 69(4):355-7. PubMed ID: 8751307
[TBL] [Abstract][Full Text] [Related]
3. Use of intravenous immunoglobulin and intravenous methylprednisolone in hyperhaemolysis syndrome in sickle cell disease.
Win N; Yeghen T; Needs M; Chen FE; Okpala I
Hematology; 2004; 9(5-6):433-6. PubMed ID: 15763986
[TBL] [Abstract][Full Text] [Related]
4. Hyperhaemolytic transfusion reaction in two β-thalassaemia major patients: The role of eculizumab.
Pantelidou D; Pilalas D; Daios S; Polychronopoulos G; Papadopoulou D; Perifanis V; Savopoulos C; Kaiafa G
J Clin Pharm Ther; 2022 Mar; 47(3):411-414. PubMed ID: 34397109
[TBL] [Abstract][Full Text] [Related]
5. Hyperhaemolytic Syndrome in Sickle Cell Disease: Clearing the Cobwebs.
Madu AJ; Ugwu AO; Efobi C
Med Princ Pract; 2021; 30(3):236-243. PubMed ID: 33176303
[TBL] [Abstract][Full Text] [Related]
6. Epidemiological and clinical features, therapeutic strategies and outcomes in patients with hyperhaemolysis: A systematic review.
Jacobs JW; Stephens LD; Allen ES; Binns TC; Booth GS; Hendrickson JE; Karafin MS; Tormey CA; Woo JS; Adkins BD
Br J Haematol; 2023 Jun; 201(6):1025-1032. PubMed ID: 37074146
[TBL] [Abstract][Full Text] [Related]
7. Delayed haemolytic transfusion reaction and hyperhaemolysis complicating peri-operative blood transfusion in sickle cell disease.
McGlennan AP; Grundy EM
Anaesthesia; 2005 Jun; 60(6):609-12. PubMed ID: 15918834
[TBL] [Abstract][Full Text] [Related]
8. Hyperhaemolysis syndrome in a patient with myelofibrosis.
Treleaven JG; Win N
Hematology; 2004 Apr; 9(2):147-9. PubMed ID: 15203871
[TBL] [Abstract][Full Text] [Related]
9. Histopathological evidence for macrophage activation driving post-transfusion hyperhaemolysis syndrome.
Win N; Lucas S; Hebballi S; McKernan A; Hamilton R; Robinson I; Chen F
Br J Haematol; 2019 Aug; 186(3):499-502. PubMed ID: 31020643
[TBL] [Abstract][Full Text] [Related]
10. Fatal Delayed Haemolytic Transfusion Reaction and Hyperhaemolysis Syndrome in a Pregnant Woman with Sickle Cell Anaemia.
Asnawi AW; Sathar J; Mohamed R; Deraman R; Kumaran S; Hamid SS; Zakaria MZ
Indian J Hematol Blood Transfus; 2016 Jun; 32(Suppl 1):251-3. PubMed ID: 27408406
[TBL] [Abstract][Full Text] [Related]
11. When a transfusion in an emergency service is not really urgent: hyperhaemolysis syndrome in a child with sickle cell disease.
Chinchilla Langeber S; Osuna Marco MP; Benedit M; Cervera Bravo Á
BMJ Case Rep; 2018 Mar; 2018():. PubMed ID: 29588281
[TBL] [Abstract][Full Text] [Related]
12. Anti-N and anti-Do
Unnikrishnan A; Pelletier JPR; Bari S; Zumberg M; Shahmohamadi A; Spiess BD; Michael MJ; Harris N; Harrell D; Mandernach MW
Transfusion; 2019 Jun; 59(6):1907-1910. PubMed ID: 30768787
[TBL] [Abstract][Full Text] [Related]
13. Hyperhaemolysis in sickle cell disease--an unusual and potentially life-threatening complication.
Stokes IC; Downie PA; Wood EM; Bowden DK; Monagle PT; Barnes CD
Med J Aust; 2010 Mar; 192(5):281-2. PubMed ID: 20201763
[TBL] [Abstract][Full Text] [Related]
14. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.
Platzbecker U; Germing U; Götze KS; Kiewe P; Mayer K; Chromik J; Radsak M; Wolff T; Zhang X; Laadem A; Sherman ML; Attie KM; Giagounidis A
Lancet Oncol; 2017 Oct; 18(10):1338-1347. PubMed ID: 28870615
[TBL] [Abstract][Full Text] [Related]
15. Treatment of post-transfusion hyperhaemolysis syndrome in Sickle Cell Disease with the anti-IL6R humanised monoclonal antibody Tocilizumab.
Sivapalaratnam S; Linpower L; Sirigireddy B; Agapidou A; Jain S; Win N; Tsitsikas DA
Br J Haematol; 2019 Sep; 186(6):e212-e214. PubMed ID: 31368112
[No Abstract] [Full Text] [Related]
16. Adverse transfusion reactions in patients with aplastic anaemia or myelodysplastic syndromes.
Moncharmont P; Quittançon E; Barday G; Benamara A;
Vox Sang; 2019 May; 114(4):349-354. PubMed ID: 30818416
[TBL] [Abstract][Full Text] [Related]
17. Life-threatening delayed hyperhemolytic transfusion reaction in a patient with sickle cell disease: effective treatment with eculizumab followed by rituximab.
Boonyasampant M; Weitz IC; Kay B; Boonchalermvichian C; Liebman HA; Shulman IA
Transfusion; 2015 Oct; 55(10):2398-403. PubMed ID: 25989361
[TBL] [Abstract][Full Text] [Related]
18. Successful management of the potentially fatal hyperhaemolysis syndrome of sickle cell anaemia with a regimen including bortezomib and Hemopure.
Epstein SS; Hadley TJ
J Clin Pharm Ther; 2019 Oct; 44(5):815-818. PubMed ID: 31237703
[TBL] [Abstract][Full Text] [Related]
19. Successful Outcome of Hyperhemolysis in Sickle Cell Disease following Multiple Lines of Treatment: The Role of Complement Inhibition.
Vlachaki E; Gavriilaki E; Kafantari K; Adamidou D; Tsitsikas D; Chasapopoulou E; Anagnostopoulos A; Tsapas A
Hemoglobin; 2018; 42(5-6):339-341. PubMed ID: 30626228
[TBL] [Abstract][Full Text] [Related]
20. Delayed haemolytic transfusion reaction in adults with sickle cell disease: a 5-year experience.
Vidler JB; Gardner K; Amenyah K; Mijovic A; Thein SL
Br J Haematol; 2015 Jun; 169(5):746-53. PubMed ID: 25753472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
